All sponsors

Sunshine Lake Pharma Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING6
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO86%

Delay Index: of 7 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +39.0 months). See all sponsors →

Open Sunshine Lake Pharma Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HEC585
NCT05060822
P2Active, not recruitingIdiopathic Pulmonary Fibrosis2702025-07-16 (+29 mo)
HEC585 dose A
NCT05139719
P2RecruitingProgressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)1102026-12 (+40 mo)
Mitizodone Phosphate tablets
NCT04984512
P2/3RecruitingDepressive Disorder, Major6002027-07 (+39 mo)
Lerotinib
NCT04415853
P3RecruitingEsophageal Cancer4162027-08 (+73 mo)
Clifutinib
NCT05586074
P3RecruitingLeukemia, Acute Myeloid (AML)3242027-11-30 (+22 mo)
Clifutinib Besylate
NCT05133882
P1/2RecruitingAcute Myeloid Leukemia, Adult1332027-12-31 (+54 mo)
HEC53856 tablet
NCT07891377
P2Not yet recruitingChemotherapy-induced Anemia; Non-Myeloid Malignancy1602028-02
HEC585
NCT07082842
P3RecruitingIdiopathic Pulmonary Fibrosis (IPF)4722031-01-15